non-small cell lung cancer

Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients

FDA Approves Foundation Medicine Test as CDx With Roche's Rozlytrek

Foundation Medicine to Provide Comprehensive Genomic Profiling Tests in Lung Cancer Screening Trial

Invitae Garners CE-IVD Mark for Two Comprehensive Genomic Profiling Tests

Genetron Health, Hutchmed Partner to Develop CDx for Lung Cancer Tyrosine Kinase Inhibitor

Blood Lipid Mass Spectrometry Assay May Enable Early-Stage Lung Cancer Detection

FDA Approves Thermo Fisher Scientific Oncomine Dx Assay as CDx for Janssen Lung Cancer Drug

FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC

Japanese Health Ministry Clears Thermo Fisher Scientific Oncomine Assay as CDx for Lung Cancer Drug

Amoy Diagnostics, Amgen Partner on Lung Cancer CDx Development for Lumakras in Japan

Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko

Agilent Technologies Obtains CE Mark for Expanded Use of PD-L1 CDx in NSCLC

FDA Approves Foundation Medicine's Liquid Biopsy Test as CDx for Novartis' Tabrecta in NSCLC

AmoyDx PCR Panel Receives Japanese Approval as CDx for Non-Small Cell Lung Cancer Therapies

Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer

FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen

FDA Approves Janssen's Rybrevant, Guardant360 CDx for EGFR Exon 20-Mutated NSCLC